According to this article in the American Journal of Clinical Nutrition, pregnant women have an even greater need for Vitamin D supplements than non-pregnant women. http://www.ajcn.org/content/79/5/717.full If she were my wife, I would have her on two Vitamin D 5000 IU gel caps — one in the morning and one in the evening 12 hours later. Vitamin D works slowly.
Posted in Featured, Health Economics / Health Communications, Pharmaeconomics Consultations 
Tags: breast cancer, colon cancer, dose, flu, health economics, immune system, nutrition, pharmaeconomics consultation, pregnancy, pregnant, Vitamin D 
Comments Off
Alzheimer’s patients need antioxidants to combat the oxidative stress that is destroying neurons in their brains. Of the many choices for antioxidants, I treated my mother with ginko biloba, selenium, and grape seed extract. Were she alive today, I would probably add acai and plant sterols to that list.
Later this year I may try Carnosine, which has been shown to reduce or eliminate advanced glycation end products. But Carnosine is somewhat expensive, and it helps with cleaning up the effects of too much serum glucose, but does not actually lower the glucose levels.
Posted in Featured, Health Economics / Health Communications, Pharmaeconomics Consultations Tags: advanced glycation end products, Benfotiamine, carnosine, HbA1C, health economics, high serum glucose, l-carnosine, persistent, pharmaeconmics consultations, Vitamin B-1, whey protein, whey protein isolate Comments OffCan you imagine the gall it would take to mark up niacin from $7 to $80? Insane! But that was my guess.
And here’s the total, as given to Dr. Spreen by a WalMart druggist: $139.08. As Dr. Spreen pointed out, you could buy the $7 niacin and still have enough left over every month to pay the lease on a small car.
Posted in Health Economics / Health Communications, Pharmaeconomics Consultations Tags: cost, generic, health economics, Niacin, Niaspan, prescription, price, Vitamin B-3 Comments Off
The drug companies have been paying user fees for more than a decade. Drug companies that hold patents benefit financially when generic applications are delayed. The OGC needs more employees to expedite reviews of the expanding backlog of generic applications. But Congress was told that no additional employees are needed in the OGC.
Posted in Health Care Law, Health Economics / Health Communications Tags: delays, drug costs, generic drug, health economics, manufacturing generic drugs, off patent, prescription drug patents Comments OffIn this position, the incumbent will work closely with the CEI leadership on comparative effectiveness research (CER) projects. In addition to following up on business leads, developing proposals and implementing sponsored research, the incumbent will help coordinate CEI activities across UBC, and will be expected to collaborate with other senior UBC scientists with expertise in CER as opportunities require. The Research Scientist/Senior Research Associate will work closely with internal research teams and clients to write study protocols, participate in the full research process, and lead/author manuscripts, abstracts, or reports for publication.